Gluten-free diet has been shown to improve gut symptoms in patients with celiac disease and also in adult patients with diagnosis of Irritable Bowel Syndrome (Rome III criteria).

Antibodies to native gliadin (AGA) have been suggested as a potential diagnostic marker of response to GFD. However, this has not been tested in a prospective study in IBS patients. Identification of predictors of a symptomatic response to GFD within the IBS population would improve the clinical management of these patients.

The purpose of this study is to evaluate the effect of gluten-free diet on gastrointestinal symptoms and gut motility in patients with Irritable Bowel Syndrome stratified according to their antigliadin antibodies status.

Additional purposes include investigating effects gluten free diet may have on other parameters:

• Improvement of mood
• Quality of life and general well-being
• Changes in gut microbiota

Inclusion Criteria:

• Adult patients
• IBS diagnosis (Rome III)
• Willingness to participate

Exclusion Criteria:

• history of any organic disease including celiac disease
• Immune deficiency
• Major abdominal surgery
• Use of immunosuppressants, glucocorticosteroids or opioids
• Use of antibiotics in the last 3 months

No plan to share data.